Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Selective Targeting of Integrin αvβ8 by a Highly Active Cyclic Peptide.

Reichart F, Maltsev OV, Kapp TG, Räder AFB, Weinmüller M, Marelli UK, Notni J, Wurzer A, Beck R, Wester HJ, Steiger K, Di Maro S, Di Leva FS, Marinelli L, Nieberler M, Reuning U, Schwaiger M, Kessler H.

J Med Chem. 2019 Feb 28;62(4):2024-2037. doi: 10.1021/acs.jmedchem.8b01588. Epub 2019 Feb 6.

PMID:
30657681
2.

Fluorescence imaging of invasive head and neck carcinoma cells with integrin αvβ6-targeting RGD-peptides: an approach to a fluorescence-assisted intraoperative cytological assessment of bony resection margins.

Nieberler M, Reuning U, Kessler H, Reichart F, Weirich G, Wolff KD.

Br J Oral Maxillofac Surg. 2018 Dec;56(10):972-978. doi: 10.1016/j.bjoms.2018.11.003. Epub 2018 Nov 28.

PMID:
30502043
3.

Differential tumor biological role of the tumor suppressor KAI1 and its splice variant in human breast cancer cells.

Miller J, Dreyer TF, Bächer AS, Sinner EK, Heinrich C, Benge A, Gross E, Preis S, Rother J, Roberts A, Nelles G, Miteva T, Reuning U.

Oncotarget. 2018 Jan 5;9(5):6369-6390. doi: 10.18632/oncotarget.23968. eCollection 2018 Jan 19.

4.

Exploring the Role of RGD-Recognizing Integrins in Cancer.

Nieberler M, Reuning U, Reichart F, Notni J, Wester HJ, Schwaiger M, Weinmüller M, Räder A, Steiger K, Kessler H.

Cancers (Basel). 2017 Sep 4;9(9). pii: E116. doi: 10.3390/cancers9090116. Review.

5.

Tissue kallikrein-related peptidase 4 (KLK4), a novel biomarker in triple-negative breast cancer.

Yang F, Aubele M, Walch A, Gross E, Napieralski R, Zhao S, Ahmed N, Kiechle M, Reuning U, Dorn J, Sweep F, Magdolen V, Schmitt M.

Biol Chem. 2017 Sep 26;398(10):1151-1164. doi: 10.1515/hsz-2017-0122.

PMID:
28755528
6.

A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins.

Kapp TG, Rechenmacher F, Neubauer S, Maltsev OV, Cavalcanti-Adam EA, Zarka R, Reuning U, Notni J, Wester HJ, Mas-Moruno C, Spatz J, Geiger B, Kessler H.

Sci Rep. 2017 Jan 11;7:39805. doi: 10.1038/srep39805.

7.

CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer.

Bronger H, Singer J, Windmüller C, Reuning U, Zech D, Delbridge C, Dorn J, Kiechle M, Schmalfeldt B, Schmitt M, Avril S.

Br J Cancer. 2016 Aug 23;115(5):553-63. doi: 10.1038/bjc.2016.172. Epub 2016 Aug 4.

8.

Stable Peptides Instead of Stapled Peptides: Highly Potent αvβ6-Selective Integrin Ligands.

Maltsev OV, Marelli UK, Kapp TG, Di Leva FS, Di Maro S, Nieberler M, Reuning U, Schwaiger M, Novellino E, Marinelli L, Kessler H.

Angew Chem Int Ed Engl. 2016 Jan 22;55(4):1535-9. doi: 10.1002/anie.201508709. Epub 2015 Dec 9.

PMID:
26663660
9.

Functional Cell Adhesion Receptors (Integrins) in Polymeric Architectures.

Zaba C, Ritz S, Tan CW, Zayni S, Müller M, Reuning U, Sinner EK.

Chembiochem. 2015 Aug 17;16(12):1740-3. doi: 10.1002/cbic.201500176. Epub 2015 Jul 14.

PMID:
26077820
10.

Synchronized cell attachment triggered by photo-activatable adhesive ligands allows QCM-based detection of early integrin binding.

Iturri J, García-Fernández L, Reuning U, García AJ, del Campo A, Salierno MJ.

Sci Rep. 2015 Mar 31;5:9533. doi: 10.1038/srep09533.

11.

Alternative splicing of KAI1 abrogates its tumor-suppressive effects on integrin αvβ3-mediated ovarian cancer biology.

Upheber S, Karle A, Miller J, Schlaugk S, Gross E, Reuning U.

Cell Signal. 2015 Mar;27(3):652-62. doi: 10.1016/j.cellsig.2014.11.028. Epub 2014 Nov 27.

PMID:
25435431
12.

Tetraspanin CD63 acts as a pro-metastatic factor via β-catenin stabilization.

Seubert B, Cui H, Simonavicius N, Honert K, Schäfer S, Reuning U, Heikenwalder M, Mari B, Krüger A.

Int J Cancer. 2015 May 15;136(10):2304-15. doi: 10.1002/ijc.29296. Epub 2014 Nov 11. Erratum in: Int J Cancer. 2016 Nov 1;139(9):E11-2.

13.

Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes.

Cui H, Seubert B, Stahl E, Dietz H, Reuning U, Moreno-Leon L, Ilie M, Hofman P, Nagase H, Mari B, Krüger A.

Oncogene. 2015 Jul;34(28):3640-50. doi: 10.1038/onc.2014.300. Epub 2014 Sep 29.

PMID:
25263437
14.

Cytoplasmic salt bridge formation in integrin αvß3 stabilizes its inactive state affecting integrin-mediated cell biological effects.

Müller MA, Brunie L, Bächer AS, Kessler H, Gottschalk KE, Reuning U.

Cell Signal. 2014 Nov;26(11):2493-503. doi: 10.1016/j.cellsig.2014.07.013. Epub 2014 Jul 17.

PMID:
25041847
15.

Selective imaging of the angiogenic relevant integrins α5β1 and αvβ3.

Neubauer S, Rechenmacher F, Beer AJ, Curnis F, Pohle K, D'Alessandria C, Wester HJ, Reuning U, Corti A, Schwaiger M, Kessler H.

Angew Chem Int Ed Engl. 2013 Oct 25;52(44):11656-9. doi: 10.1002/anie.201306376. Epub 2013 Sep 20.

PMID:
24115324
16.

The glycophorin A transmembrane sequence within integrin αvβ3 creates a non-signaling integrin with low basal affinity that is strongly adhesive under force.

Müller MA, Opfer J, Brunie L, Volkhardt LA, Sinner EK, Boettiger D, Bochen A, Kessler H, Gottschalk KE, Reuning U.

J Mol Biol. 2013 Aug 23;425(16):2988-3006. doi: 10.1016/j.jmb.2013.05.020. Epub 2013 May 28.

PMID:
23727145
17.

High expression of crystallin αB represents an independent molecular marker for unfavourable ovarian cancer patient outcome and impairs TRAIL- and cisplatin-induced apoptosis in human ovarian cancer cells.

Volkmann J, Reuning U, Rudelius M, Häfner N, Schuster T, Becker V Ros A, Weimer J, Hilpert F, Kiechle M, Dürst M, Arnold N, Schmalfeldt B, Meindl A, Ramser J.

Int J Cancer. 2013 Jun 15;132(12):2820-32. doi: 10.1002/ijc.27975. Epub 2012 Dec 27.

18.

Behavior of primary human osteoblasts on trimmed and sandblasted Ti6Al4V surfaces functionalized with integrin αvβ3-selective cyclic RGD peptides.

Mas-Moruno C, Dorfner PM, Manzenrieder F, Neubauer S, Reuning U, Burgkart R, Kessler H.

J Biomed Mater Res A. 2013 Jan;101(1):87-97. doi: 10.1002/jbm.a.34303. Epub 2012 Jul 24.

PMID:
22826207
19.

A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire.

Saucedo-Zeni N, Mewes S, Niestroj R, Gasiorowski L, Murawa D, Nowaczyk P, Tomasi T, Weber E, Dworacki G, Morgenthaler NG, Jansen H, Propping C, Sterzynska K, Dyszkiewicz W, Zabel M, Kiechle M, Reuning U, Schmitt M, Lücke K.

Int J Oncol. 2012 Oct;41(4):1241-50. doi: 10.3892/ijo.2012.1557. Epub 2012 Jul 16.

20.

Vitronectin in vascular context: facets of a multitalented matricellular protein.

Preissner KT, Reuning U.

Semin Thromb Hemost. 2011 Jun;37(4):408-24. doi: 10.1055/s-0031-1276590. Epub 2011 Jul 30. Review.

PMID:
21805447
21.
22.

Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.

Schmitt M, Mengele K, Napieralski R, Magdolen V, Reuning U, Gkazepis A, Sweep F, Brünner N, Foekens J, Harbeck N.

Expert Rev Mol Diagn. 2010 Nov;10(8):1051-67. doi: 10.1586/erm.10.71. Review.

PMID:
21080821
23.

Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.

Mengele K, Napieralski R, Magdolen V, Reuning U, Gkazepis A, Sweep F, Brünner N, Foekens J, Harbeck N, Schmitt M.

Expert Rev Mol Diagn. 2010 Oct;10(7):947-62. doi: 10.1586/erm.10.73. Review.

PMID:
20964613
24.

Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo.

Sato S, Kopitz C, Grismayer B, Beaufort N, Reuning U, Schmitt M, Luther T, Kotzsch M, Krüger A, Magdolen V.

Breast Cancer Res Treat. 2011 Jun;127(3):649-57. doi: 10.1007/s10549-010-1042-5. Epub 2010 Jul 16.

PMID:
20635136
25.

Tumor suppressor KAI1 affects integrin alphavbeta3-mediated ovarian cancer cell adhesion, motility, and proliferation.

Ruseva Z, Geiger PX, Hutzler P, Kotzsch M, Luber B, Schmitt M, Gross E, Reuning U.

Exp Cell Res. 2009 Jun 10;315(10):1759-71. doi: 10.1016/j.yexcr.2009.01.007. Epub 2009 Jan 22.

PMID:
19371633
26.

Integrin alphavbeta3 upregulates integrin-linked kinase expression in human ovarian cancer cells via enhancement of ILK gene transcription.

Lössner D, Abou-Ajram C, Benge A, Aumercier M, Schmitt M, Reuning U.

J Cell Physiol. 2009 Aug;220(2):367-75. doi: 10.1002/jcp.21774.

PMID:
19334037
27.

Integrin alphavbeta3 mediates upregulation of epidermal growth-factor receptor expression and activity in human ovarian cancer cells.

Lössner D, Abou-Ajram C, Benge A, Reuning U.

Int J Biochem Cell Biol. 2008;40(12):2746-61. doi: 10.1016/j.biocel.2008.05.014. Epub 2008 Jun 5.

PMID:
18577466
28.

Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects.

Schmitt M, Mengele K, Gkazepis A, Napieralski R, Magdolen V, Reuning U, Harbeck N.

Breast Care (Basel). 2008;3(s2):3-10. Epub 2008 Oct 15. No abstract available.

29.

Binding of small mono- and oligomeric integrin ligands to membrane-embedded integrins monitored by surface plasmon-enhanced fluorescence spectroscopy.

Lössner D, Kessler H, Thumshirn G, Dahmen C, Wiltschi B, Tanaka M, Knoll W, Sinner EK, Reuning U.

Anal Chem. 2006 Jul 1;78(13):4524-33.

PMID:
16808462
30.

In vivo detection of membrane protein expression using surface plasmon enhanced fluorescence spectroscopy (SPFS).

Krupka SS, Wiltschi B, Reuning U, Hölscher K, Hara M, Sinner EK.

Biosens Bioelectron. 2006 Aug 15;22(2):260-7. Epub 2006 Mar 10.

PMID:
16530398
31.
32.

High hydrostatic pressure-induced cell death in human chondrocytes and chondrosarcoma cells.

Naal FD, Mengele K, Schauwecker J, Gollwitzer H, Gerdesmeyer L, Reuning U, Mittelmeier W, Gradinger R, Schmitt M, Diehl P.

Anticancer Res. 2005 May-Jun;25(3B):1977-82.

33.

[Tumor-associated prognostic factors of the plasminogen activator family: determination and clinical value of u-PA, t-PA, PAI-1, and PAI-2].

Mengele K, Harbeck N, Reuning U, Magdolen V, Schmitt M.

Hamostaseologie. 2005 Aug;25(3):301-10. German.

PMID:
16113755
34.

ADAM15 decreases integrin alphavbeta3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion.

Beck V, Herold H, Benge A, Luber B, Hutzler P, Tschesche H, Kessler H, Schmitt M, Geppert HG, Reuning U.

Int J Biochem Cell Biol. 2005 Mar;37(3):590-603.

PMID:
15618016
35.

Monitoring of integrin-mediated adhesion of human ovarian cancer cells to model protein surfaces by quartz crystal resonators: evaluation in the impedance analysis mode.

Li J, Thielemann C, Reuning U, Johannsmann D.

Biosens Bioelectron. 2005 Jan 15;20(7):1333-40. Erratum in: Biosens Bioelectron. 2005 May 15;20(11):2386.

PMID:
15590287
36.

Incorporation of integrins into artificial planar lipid membranes: characterization by plasmon-enhanced fluorescence spectroscopy.

Sinner EK, Reuning U, Kök FN, Saccà B, Moroder L, Knoll W, Oesterhelt D.

Anal Biochem. 2004 Oct 15;333(2):216-24.

PMID:
15450795
37.

Effect of extracorporal high hydrostatic pressure on tumor cell adherence and viability.

Diehl P, Reuning U, Gollwitzer H, Magdolen U, Gerdesmeyer L, Schauwecker J, Tuebel J, Gradinger R, Mittelmeier W, Schmitt M.

Oncol Rep. 2004 Aug;12(2):369-73.

PMID:
15254704
38.

Beta-catenin up-regulates the expression of the urokinase plasminogen activator in human colorectal tumors.

Hiendlmeyer E, Regus S, Wassermann S, Hlubek F, Haynl A, Dimmler A, Koch C, Knoll C, van Beest M, Reuning U, Brabletz T, Kirchner T, Jung A.

Cancer Res. 2004 Feb 15;64(4):1209-14.

39.

Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins.

Reuning U, Magdolen V, Hapke S, Schmitt M.

Biol Chem. 2003 Aug;384(8):1119-31. Review.

PMID:
12974381
40.

Ovarian cancer cell proliferation and motility is induced by engagement of integrin alpha(v)beta3/Vitronectin interaction.

Hapke S, Kessler H, Luber B, Benge A, Hutzler P, Höfler H, Schmitt M, Reuning U.

Biol Chem. 2003 Jul;384(7):1073-83.

PMID:
12956424
41.

Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo.

Reuning U, Sperl S, Kopitz C, Kessler H, Krüger A, Schmitt M, Magdolen V.

Curr Pharm Des. 2003;9(19):1529-43. Review.

PMID:
12871066
42.

Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo.

Magdolen V, Krüger A, Sato S, Nagel J, Sperl S, Reuning U, Rettenberger P, Magdolen U, Schmitt M.

Recent Results Cancer Res. 2003;162:43-63. Review.

PMID:
12790320
43.

Theme Issue: update on the role of the fibrinolysis/plasminogen activation system in a cellular context.

Schmitt M, Magdolen V, Reuning U.

Thromb Haemost. 2003 Apr;89(4):596-8. No abstract available.

PMID:
12669111
44.

Motility enhancement by tumor-derived mutant E-cadherin is sensitive to treatment with epidermal growth factor receptor and phosphatidylinositol 3-kinase inhibitors.

Fuchs M, Hutzler P, Brunner I, Schlegel J, Mages J, Reuning U, Hapke S, Duyster J, Hirohashi S, Genda T, Sakamoto M, Uberall F, Höfler H, Becker KF, Luber B.

Exp Cell Res. 2002 Jun 10;276(2):129-41.

PMID:
12027444
45.

High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice.

Lutz V, Reuning U, Krüger A, Luther T, von Steinburg SP, Graeff H, Schmitt M, Wilhelm OG, Magdolen V.

Biol Chem. 2001 May;382(5):789-98.

PMID:
11517932
46.

Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells.

Hapke S, Kessler H, Arroyo de Prada N, Benge A, Schmitt M, Lengyel E, Reuning U.

J Biol Chem. 2001 Jul 13;276(28):26340-8. Epub 2001 Apr 30.

47.

beta(3)A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter.

Hapke S, Gawaz M, Dehne K, Köhler J, Marshall JF, Graeff H, Schmitt M, Reuning U, Lengyel E.

Mol Cell Biol. 2001 Mar;21(6):2118-32.

48.

RFLP Molecular Analysis of the Urokinase-Type Plasminogen Activator Gene.

Muehlenweg B, Schnelzer A, Türkmen B, Lengyel E, Reuning U, Graeff H, Schmitt M, Magdolen V.

Methods Mol Med. 2001;39:299-306. doi: 10.1385/1-59259-071-3:299.

PMID:
21340784
49.

Natural and synthetic inhibitors of the tumor-associated serine protease urokinase-type plasminogen activator.

Magdolen V, Arroyo de Prada N, Sperl S, Muehlenweg B, Luther T, Wilhelm OG, Magdolen U, Graeff H, Reuning U, Schmitt M.

Adv Exp Med Biol. 2000;477:331-41. Review. No abstract available.

PMID:
10849761
50.

Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting.

Haubner R, Wester HJ, Reuning U, Senekowitsch-Schmidtke R, Diefenbach B, Kessler H, Stöcklin G, Schwaiger M.

J Nucl Med. 1999 Jun;40(6):1061-71.

Supplemental Content

Loading ...
Support Center